Similar articles

• Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.

  Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J. Krieter P, et al. J Clin Pharmacol. 2016 Oct;56(10):1243-53. doi: 10.1002/jcph.759. Epub 2016 Jun 10. J Clin Pharmacol. 2016. PMID: 27145977
• Easy-to-use overdose antidote earns fast-track approval.

  Kuehn BM. Kuehn BM. JAMA. 2014 Apr 23-30;311(16):1600. doi: 10.1001/jama.2014.4483. JAMA. 2014. PMID: 24756492 No abstract available.
• In brief: Higher-dose naloxone nasal spray (Kloxxado) for opioid overdose.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Sep 20;63(1633):151-152. Med Lett Drugs Ther. 2021. PMID: 34550963 No abstract available.
• Naloxone nasal spray.

  [No authors listed] [No authors listed] Drug Ther Bull. 2019 Sep;57(9):137-140. doi: 10.1136/dtb.2019.000035. Epub 2019 Jul 11. Drug Ther Bull. 2019. PMID: 31296655 Review. No abstract available.
• Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems.

  Elzey MJ, Fudin J, Edwards ES. Elzey MJ, et al. Expert Opin Drug Deliv. 2017 Sep;14(9):1045-1058. doi: 10.1080/17425247.2017.1230097. Epub 2016 Sep 16. Expert Opin Drug Deliv. 2017. PMID: 27606669 Review.